The aim of our study was to explore the value of second-line treatment for advanced non-small cell lung cancer (NSCLC). One patient with metastatic adenocarcinoma of NSCLC was given second-line treatment of pemertrexe...The aim of our study was to explore the value of second-line treatment for advanced non-small cell lung cancer (NSCLC). One patient with metastatic adenocarcinoma of NSCLC was given second-line treatment of pemertrexed/cisplatin. Follow-up was made to observe progression free survival (PFS) and survival time. She was given 4 cycles first-line treatment of recombinant human endostatin plus gemcitabine/cisplatin previously; the efficacy was CR and PFS was 10.2 months. After the 5th cycle treatment of pemetrexed/cisplatin, the efficacy of the primary tumor was CR, and bone metastases was stable. PFS was 6.6 months, and the patient has been survival for 22 months. Quality of life (QOL) of the patient was improved. When advanced NSCLC is recurrence or metastasis, starting second-line treatment of pemetrexed/cisplatin timely can prolong survival time and improve QOL.展开更多
A 43-year-old female with a 3-month history of paroxysmal irritating cough presented progressive chest tightness and shortness of breath.Laboratory data showed elevated carcino-embryonic antigen(CEA).Further imaging s...A 43-year-old female with a 3-month history of paroxysmal irritating cough presented progressive chest tightness and shortness of breath.Laboratory data showed elevated carcino-embryonic antigen(CEA).Further imaging studies revealed a soft tissue mass shadow was in right middle lobe lung with mediastinal and sub-carinal lymph nodes enlarged.Biopsy diagnosis:moderately and poorly differentiated adenocarcinoma of the lung.Clinical diagnosis:central non-small cell lung cancer(NSCLC) of right middle lobe(CIVT4N2M1),lung adenocarcinoma G2-3,malignant pleural effusion,pericardial effusion,hilar and mediastina lymph node metastases.After 4 cycles of endostar plus GC therapy,imaging studies revealed showed soft tissue mass in right middle lobe disappeared,and evaluation of short-term result was complete remission(CR).PFS has been seven months till now.Therefore,this report provided strong evidence that endostatin combined GC treatment for advanced NSCLC is safe and effective,which can prolong survival and improve quality of life.展开更多
The treatment of gastric carcinoma consists of neoadjuvant chemoradiation,partial gastrectomy,subtotal gastrectomy,total gastrectomy,extended resection,and postoperative chemotherapy.Currently,gastrectomy and extended...The treatment of gastric carcinoma consists of neoadjuvant chemoradiation,partial gastrectomy,subtotal gastrectomy,total gastrectomy,extended resection,and postoperative chemotherapy.Currently,gastrectomy and extended lymphadenectomy is the optimal choice for late gastric carcinoma.Postoperative complications are common after total gastrectomy including hemorrhage,anastomotic leakage,f istula,and obstruction.However,deep venous thrombosis(DVT) is an uncommon complication after gastrectomy for gastric carcinoma.We describe a case of a 68-year-old female patient with DVT after gastrectomy for gastric carcinoma.The patient was treated with anticoagulants and thrombolytics and subjected to necessary laboratory monitoring.The patient recovered well after treatment and was symptom-free during a 3-mo follow-up.We conclude that correct diagnosis and treatment of DVT are crucial.展开更多
文摘The aim of our study was to explore the value of second-line treatment for advanced non-small cell lung cancer (NSCLC). One patient with metastatic adenocarcinoma of NSCLC was given second-line treatment of pemertrexed/cisplatin. Follow-up was made to observe progression free survival (PFS) and survival time. She was given 4 cycles first-line treatment of recombinant human endostatin plus gemcitabine/cisplatin previously; the efficacy was CR and PFS was 10.2 months. After the 5th cycle treatment of pemetrexed/cisplatin, the efficacy of the primary tumor was CR, and bone metastases was stable. PFS was 6.6 months, and the patient has been survival for 22 months. Quality of life (QOL) of the patient was improved. When advanced NSCLC is recurrence or metastasis, starting second-line treatment of pemetrexed/cisplatin timely can prolong survival time and improve QOL.
文摘A 43-year-old female with a 3-month history of paroxysmal irritating cough presented progressive chest tightness and shortness of breath.Laboratory data showed elevated carcino-embryonic antigen(CEA).Further imaging studies revealed a soft tissue mass shadow was in right middle lobe lung with mediastinal and sub-carinal lymph nodes enlarged.Biopsy diagnosis:moderately and poorly differentiated adenocarcinoma of the lung.Clinical diagnosis:central non-small cell lung cancer(NSCLC) of right middle lobe(CIVT4N2M1),lung adenocarcinoma G2-3,malignant pleural effusion,pericardial effusion,hilar and mediastina lymph node metastases.After 4 cycles of endostar plus GC therapy,imaging studies revealed showed soft tissue mass in right middle lobe disappeared,and evaluation of short-term result was complete remission(CR).PFS has been seven months till now.Therefore,this report provided strong evidence that endostatin combined GC treatment for advanced NSCLC is safe and effective,which can prolong survival and improve quality of life.
文摘The treatment of gastric carcinoma consists of neoadjuvant chemoradiation,partial gastrectomy,subtotal gastrectomy,total gastrectomy,extended resection,and postoperative chemotherapy.Currently,gastrectomy and extended lymphadenectomy is the optimal choice for late gastric carcinoma.Postoperative complications are common after total gastrectomy including hemorrhage,anastomotic leakage,f istula,and obstruction.However,deep venous thrombosis(DVT) is an uncommon complication after gastrectomy for gastric carcinoma.We describe a case of a 68-year-old female patient with DVT after gastrectomy for gastric carcinoma.The patient was treated with anticoagulants and thrombolytics and subjected to necessary laboratory monitoring.The patient recovered well after treatment and was symptom-free during a 3-mo follow-up.We conclude that correct diagnosis and treatment of DVT are crucial.
